Table 1.
Patient Characteristics at Baseline. Values Are Given as Mean ± SD or as Absolute Percentage
| Parameter | Total | PIO | RAM | PIRA |
|---|---|---|---|---|
| n | 149 | 52 | 44 | 53 |
| Gender (male/female) | 72/77 | 22/30 | 25/19 | 25/28 |
| Age (years) | 60 ± 9 | 60 ± 9 | 61 ± 9 | 60 ± 8 |
| Body mass index (kg/m2) | 30.4 ± 4.7 | 29.9 ± 4.6 | 30.5 ± 4.3 | 30.8 ± 5.1 |
| Duration of hypertension (years) | 9.4 ± 8.4 | 8.9 ± 7.7 | 10.8 ± 10.1 | 8.6 ± 7.4 |
| Smoker | 20 (13.4%) | 6 (11.5%) | 6 (13.6%) | 8 (15.1%) |
| Blood pressure (mm Hg) | ||||
| Systolic | 128 ± 11 | 128 ± 11 | 129 ± 12 | 128 ± 10 |
| Diastolic | 78 ± 8 | 78 ± 9 | 76 ± 8 | 79 ± 7 |
| RAS inhibitors | 100% | 100% | 100% | 100% |
| Ramipril | 42.3% | 36.5% | 40.9% | 49.1% |
| β-blockers | 36.2% | 34.6% | 38.6% | 35.8% |
| Diuretics | 22.8% | 21.2% | 18.2% | 28.3% |
| Calcium channel blockers | 21.5% | 23.1% | 25.0% | 17.0% |
| Centrally acting antihypertensives | 7.4% | 7.7% | 9.1% | 5.7% |
| Antilipidemic treatment | ||||
| Statins | 19.5% | 17.3% | 20.5% | 20.8% |
| Ezetimibe | 2.0% | 0% | 4.5% | 1.9% |